Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial.

Abstract

OBJECTIVE To evaluate the safety and efficacy of ocrelizumab plus methotrexate (MTX) or leflunomide (LEF) in patients with active rheumatoid arthritis (RA) and an inadequate response to tumor necrosis factor α inhibitors. METHODS This was a multicenter randomized, double-blind, placebo-controlled, parallel-group study that continued over 48 weeks… (More)

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.